Chiara Zecca, Gianna C Riccitelli, Pasquale Calabrese, Emanuele Pravatà, Ursula Candrian, Charles RG Guttmann, Claudio Gobbi
Abstract
De-escalating natalizumab (NTZ) to interferon beta 1b (IFN B 1B) is a possible treatment option in multiple sclerosis (MS) patients interrupting NTZ because of increased risk of progressive multifocal leukoencephalopathy (PML). The aim of this study was to evaluate satisfaction and adherence to treatment, behavioral and fatigue changes in patients switched to IFN B 1B compared to continued NTZ treatment.
Pharmacology, Toxicology and Pharmaceutical Science
6
6%
Other
14
14%
Unknown
35
35%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2014.
All research outputs
#3,767,593
of 26,505,350 outputs
Outputs from BMC Neurology
#437
of 2,789 outputs
Outputs of similar age
#35,164
of 236,592 outputs
Outputs of similar age from BMC Neurology
#9
of 68 outputs
Altmetric has tracked 26,505,350 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,789 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 236,592 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.
